Device Trial Radar · NCT07354178
Study of Collagen-Based Thrombin Hemostat for the Control of Bleeding in Spinal Surgery
Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
130
Actual
Start
Oct 22, 2024
Primary completion
Jun 19, 2025
Study completion Aug 18, 2025
Sponsor
- Lead sponsor
- DALIM TISSEN Co., Ltd.Not on our public-company list
- Sponsor type
- Industry
- First posted
- Jan 21, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 20 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This clinical trial evaluated the effectiveness and safety of a collagen-based hemostatic agent containing thrombin in patients undergoing spinal surgery. The study compared this investigational product with an existing hemostatic agent to assess whether it performed equally well in controlling surgical bleeding. Patients with spinal stenosis, tumors, or trauma who required spinal surgery were enrolled. The hemostat was applied intraoperatively when grade 3 bleeding was observed. The study assessed hemostatic performance and safety of the product when used during surgery.
Conditions
- Spinal Tumor
- Spinal Injury
- Hemostasis
- Spinal Stenosis
- Spinal Surgery
- Intraoperative Bleeding
Interventions
CollaStat®Device
Clinical subjects are enrolled after the clinical investigator confirms that there are bleeding sites where hemostasis by normal procedures (compression, suturing, electrosurgical scalpel, etc.) is ineffective or difficult to perform. To arrest intraoperative bleeding, the study group is treated with Dalim Tissen's CollaStat® and compressed with general gauze.
Floseal®Device
Clinical subjects are enrolled after the clinical investigator confirms that there are bleeding sites where hemostasis by normal procedures (compression, suturing, electrosurgical scalpel, etc.) is ineffective or difficult to perform. To arrest intraoperative bleeding, the control group is treated with Baxter's Floseal® and compressed with general gauze
Primary outcomes
What the sponsor says the trial is designed to measure.
- Hemostasis success rateTime frame: Hemostasis at the first bleeding site is confirmed at 1 minute, 2 minutes, 3 minutes, 6 minutes, and 10 minutes
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Gangnam Severance Hospital
Seoul, Gangnam-gu, South Korea
Yongin Severance Hospital
Yongin-si, Giheung-gu, South Korea
Severance Hospital, Yonsei University Health Syetem
Seoul, Seodaemun-gu, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.